<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02674321</url>
  </required_header>
  <id_info>
    <org_study_id>SD-809-C-17</org_study_id>
    <nct_id>NCT02674321</nct_id>
  </id_info>
  <brief_title>A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)</brief_title>
  <official_title>A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auspex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability and preliminary efficacy of
      SD-809 in the treatment of motor and phonic tics of Tourette Syndrome and to evaluate the
      pharmacokinetic of SD-809 and its metabolites.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>8 weeks</time_frame>
    <description>Incidence of adverse events (AEs), serious AEs, severe AEs, drug related AEs, AEs leading to withdrawal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total Tic Score of the Yale Global Tic Severity Scale (YGTSS)</measure>
    <time_frame>Baseline, Weeks 2, 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Impairment Score of the Yale Global Tic Severity Scale (YGTSS)</measure>
    <time_frame>Baseline, Weeks 2, 4, and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Global Severity Score of the Yale Global Tic Severity Scale (YGTSS)</measure>
    <time_frame>Baseline, Weeks 2, 4, and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Tourette Syndrome Clinical Global Impression</measure>
    <time_frame>Baseline, Weeks 2, 4, and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (TS-PGIC)</measure>
    <time_frame>Weeks 2, 4, and 8</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>TOURETTE SYNDROME</condition>
  <arm_group>
    <arm_group_label>SD-809</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• SD-809 tablets taken once or twice daily for 8 weeks, includes a dose titration period and a maintenance period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SD-809</intervention_name>
    <arm_group_label>SD-809</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12 to 18 years of age, inclusive, at Screening.

          -  Patient has a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
             (DSM-V) diagnosis of Tourette Syndrome and has manifested motor and phonic tics within
             3 months before the Screening visit

          -  Patient has total tic score of ≥19 on the YGTSS

          -  Tic severity and frequency has been stable for at least 2 weeks before the Screening
             visit

          -  Willing to adhere to medication regimen and to comply with all procedures

          -  Patient is in good general health, as indicated by medical and psychiatric history and
             physical examination

          -  Patient and parent/guardian have provided written, informed consent (and written
             assent, as appropriate)

          -  Female patients of childbearing potential agree to use an acceptable method of
             contraception

               -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  Patient has a serious untreated or undertreated psychiatric illness

          -  Patient has a history of suicidal ideation or behavior

          -  Patient has received tetrabenazine, neuroleptics, benzodiazepines, topiramate,
             dopamine receptor antagonists within 14 days of Screening or Baseline; or botulinum
             toxin within 3 months of Screening or Baseline

          -  Patient is being treated with deep brain stimulation for control of tics

          -  Patient has a progressive or degenerative neurological disorder or a structural
             disorder of the brain

          -  Patient has participated in an investigational drug or device trial within 30 days of
             Screening

          -  Patient is pregnant or breastfeeding at Screening or Baseline

          -  Patient has a history of alcohol or substance abuse in the previous 12 months, as
             defined in the DSM-V

               -  Additional criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site #101</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tourette Syndrome</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Tourette Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

